80/100BStryker stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Stryker is 354.47, 13.1% above the current price of 313.46. Their targets range from 309.00 to 407.00.
Of the 20 firms that rated Stryker in the past 12 months, 14 rate it buy or strong buy, 6 hold and 0 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 309.00 to 407.00, with an average of 354.47.
| Buy | 14 | |
| Hold | 6 | |
| Sell | 0 |
12-month price target
| Highest target | 407.00 |
| Average target | 354.47 |
| Lowest target | 309.00 |
| Current price | 313.46 |
Stryker price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Stryker price target and rating?
How analysts rate Stryker, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
14 of 20 firms rate it buy now, against 12 of 15 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Stryker analyst upgrades, downgrades and price targets
The latest rating change came on 30 October 2026, when Canaccord Genuity downgraded Stryker from Buy to Hold. The most recent new target came from Stifel Nicolaus on 2 November 2026: 325.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 2 Nov 2026 | Stifel Nicolaus Rick Wise | Reiterated · Buy | 330.00 → 325.00 | -1.5% | 291.86 |
| 30 Oct 2026 | BMO Capital Vik Chopra | — | 317.00 → 309.00 | -2.5% | 296.00 |
| 30 Oct 2026 | RBC Capital Shagun Singh | Reiterated · Outperform | 420.00 → 375.00 | -10.7% | 295.08 |
| 30 Oct 2026 | Raymond James Jayson Bedford | — | 370.00 → 323.00 | -12.7% | 311.36 |
| 30 Oct 2026 | Needham Mike Matson | Reiterated · Buy | 418.00 → 359.00 | -14.1% | 311.36 |
| 30 Oct 2026 | Canaccord Genuity | Downgraded · Buy → Hold | — | — | — |
| 12 Oct 2026 | BTIG Ryan Zimmerman | Reiterated · Buy | 358.00 → 316.00 | -11.7% | 279.83 |
| 6 Oct 2026 | Barclays | — | 394.00 → 375.00 | -4.8% | 278.50 |
| 6 Oct 2026 | Truist Financial | — | 330.00 → 310.00 | -6.1% | 280.23 |
| 30 Sept 2026 | Stifel Nicolaus | Reiterated · Buy | 330.00 | — | 278.86 |
| 18 Sept 2026 | Canaccord Genuity | Reiterated · Buy | 385.00 | — | 280.14 |
| 9 Sept 2026 | BMO Capital Joanne Wuensch | — | 369.00 → 317.00 | -14.1% | 277.89 |
| 9 Sept 2026 | Wells Fargo Larry Biegelsen | Reiterated · Overweight | 348.00 | — | 276.43 |
| 13 Aug 2026 | Wolfe Research | Downgraded · Outperform → Peer Perform | — | — | — |
| 31 Jul 2026 | RBC Capital Shagun Singh | Reiterated · Outperform | 435.00 → 420.00 | -3.4% | 321.09 |
| 31 Jul 2026 | Raymond James | — | 418.00 → 370.00 | -11.5% | 322.69 |
| 31 Jul 2026 | BTIG Ryan Zimmerman | Reiterated · Buy | 371.00 → 358.00 | -3.5% | 322.13 |
| 31 Jul 2026 | Piper Sandler | Reiterated · Overweight | 390.00 | — | 348.37 |
| 31 Jul 2026 | Wolfe Research | — | 375.00 | — | 348.37 |
| 13 Jul 2026 | BTIG | — | 379.00 → 371.00 | -2.1% | 329.78 |
| 9 Jul 2026 | Argus Research | — | 370.00 | — | 328.79 |
| 9 Jul 2026 | BMO Capital | Upgraded · Market Perform → Outperform | — | — | — |
| 8 Jul 2026 | BMO Capital | — | 369.00 | — | 326.85 |
| 6 Jul 2026 | Evercore ISI | Reiterated · Outperform | 355.00 → 350.00 | -1.4% | 319.22 |
| 5 Jun 2026 | Leerink Partners Mike Kratky | Reiterated · Outperform | 407.00 | — | 301.21 |
| 4 May 2026 | Truist Financial Richard Newitter | Reiterated · Hold | 400.00 → 330.00 | -17.5% | 293.44 |
| 4 May 2026 | Barclays Matt Miksic | Reiterated · Overweight | 469.00 → 394.00 | -16.0% | 294.73 |
| 1 May 2026 | Goldman Sachs David Roman | — | 399.00 → 361.00 | -9.5% | 294.73 |
| 1 May 2026 | Bernstein | — | 465.00 → 410.00 | -11.8% | 302.38 |
| 1 May 2026 | Robert W. Baird | — | 437.00 → 385.00 | -11.9% | 307.87 |
| 1 May 2026 | Evercore ISI | Reiterated · Outperform | 390.00 → 355.00 | -9.0% | 308.17 |
| 1 May 2026 | BTIG | Reiterated · Buy | 412.00 → 379.00 | -8.0% | 315.18 |
| 1 May 2026 | Needham | Reiterated · Buy | 454.00 → 418.00 | -7.9% | 315.18 |
| 1 May 2026 | Deutsche Bank | — | 315.00 | — | 315.18 |
| 4 Mar 2026 | Jefferies Matthew Taylor | — | 465.00 | — | 381.89 |
| 24 Feb 2026 | UBS | Reiterated · Neutral | 408.00 → 400.00 | -2.0% | 381.83 |
| 2 Feb 2026 | Barclays | Reiterated · Overweight | 469.00 | — | 369.56 |
| 30 Jan 2026 | Needham Mike Matson | Reiterated · Buy | 448.00 → 454.00 | +1.3% | 365.62 |
| 30 Jan 2026 | Robert W. Baird | — | 437.00 | — | 369.02 |
| 30 Jan 2026 | BTIG Ryan Zimmerman | Reiterated · Buy | 403.00 → 412.00 | +2.2% | 354.30 |
| 9 Jan 2026 | Bernstein Lee Hambright | Reiterated · Outperform | 450.00 → 465.00 | +3.3% | 367.21 |
| 9 Jan 2026 | Goldman Sachs | — | 422.00 → 399.00 | -5.5% | 367.21 |
| 6 Jan 2026 | Raymond James | — | 418.00 | — | 348.79 |
| 5 Jan 2026 | Evercore ISI | — | 405.00 → 390.00 | -3.7% | 347.69 |
| 19 Dec 2025 | Citizens | Upgraded · Market Perform → Market Outperform | — | — | — |
| 14 Nov 2025 | Truist Financial Richard Newitter | Reiterated · Hold | 392.00 → 400.00 | +2.0% | 366.38 |
| 14 Nov 2025 | RBC Capital Shagun Singh | — | 435.00 | — | 365.14 |
| 14 Nov 2025 | Needham Mike Matson | Reiterated · Buy | 448.00 | — | 373.42 |
Stryker EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Stryker's EPS to grow 29.1% a year until 2028, faster than over the last 5 years (14.9% a year) and the last 3 years (10.8%).
Analysts expect Stryker's revenue to grow 7.1% a year until 2028, slower than over the last 5 years (11.8% a year) and the last 3 years (10.8%).
Revenue
EPS
Does Stryker beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 4.1% off the result, either way, and their revenue estimate 1.9%, over the last 12 quarters.
- EPS beats
- 74 / 136
- Revenue beats
- 73 / 120
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +1.9%
- Since
- January 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 29 Oct 2026 | 3.55 | 3.52 | -0.8% | 6.62B | 6.52B | -1.5% |
| Q2 FY2026 | 30 Jul 2026 | 3.49 | 3.69 | +5.7% | 6.58B | 6.59B | +0.1% |
| Q1 FY2026 | 30 Apr 2026 | 2.98 | 2.60 | -12.8% | 6.34B | 6.02B | -5.0% |
| Q4 FY2025 | 29 Jan 2026 | 4.40 | 4.47 | +1.6% | 7.12B | 7.17B | +0.7% |
| Q3 FY2025 | 30 Oct 2025 | 3.13 | 3.19 | +1.9% | 6.04B | 6.06B | +0.2% |
| Q2 FY2025 | 31 Jul 2025 | 3.07 | 3.13 | +2.0% | 5.94B | 6.02B | +1.4% |
| Q1 FY2025 | 1 May 2025 | 2.71 | 2.84 | +4.8% | 5.69B | 5.87B | +3.1% |
| Q4 FY2024 | 28 Jan 2025 | 3.87 | 4.01 | +3.6% | 6.36B | 6.44B | +1.2% |
| Q3 FY2024 | 29 Oct 2024 | 2.77 | 2.87 | +3.6% | 5.37B | 5.49B | +2.3% |
| Q2 FY2024 | 30 Jul 2024 | 2.79 | 2.81 | +0.7% | 5.40B | 5.42B | +0.3% |
| Q1 FY2024 | 30 Apr 2024 | 2.35 | 2.50 | +6.4% | 5.10B | 5.24B | +2.7% |
| Q4 FY2023 | 30 Jan 2024 | 3.27 | 3.46 | +5.8% | 5.60B | 5.82B | +3.9% |
Stryker stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Stryker's earnings keep growing at the 9.9% a year analysts expect to FY2028, it would earn about 21.86 a share in FY2030. At the P/E it has traded at over the last five years (33.2 to 50.6) that is 724.98 to 1,104.88 a share, or 896.40 at its average P/E of 41.0. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 14.84 | 492.10 | 608.45 | 749.97 |
| FY2027 | 16.31 | 540.87 | 668.75 | 824.29 |
| FY2028 | 18.09 | 600.20 | 742.11 | 914.71 |
| FY2029 (extrapolated) | 19.89 | 659.65 | 815.61 | 1,005.31 |
| FY2030 (extrapolated) | 21.86 | 724.98 | 896.40 | 1,104.88 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 9.9% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (33.2, 41.0, 50.6).
Is Stryker stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Stryker's P/E of 33.2 is near the bottom of its 5-year range (31.6 to 55.0, median 42.3). It is within 5% of its 5-year low. Analysts do not expect slower growth than in recent years, so it is cheaper than its usual level. Buyers pay less for each point of growth than usual: a PEG of 1.1 on expected growth against 2.8 on its median P/E and past five years' growth. At its usual P/E (42.3 × EPS of 9.45), Stryker's fair value is 399.65; the price, 313.46, is 21.6% below it. Its forward P/E, on the consensus for FY2026, is 21.1.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (31.6 and 55.0). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 33.17
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 42.29
- Five-year P/E range
- 31.6 – 55.0
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 21.13
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 3.35
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +13.1%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.850 | 71.4258Price 35.85193 | +99.2% | |
| 29.050 | 56.2634Price 29.0596 | +93.7% | |
| 241.000 | 464.49205Price 241.00627 | +92.7% | |
| 123.590 | 237.24178Price 123.59297 | +92.0% | |
| 161.400 | 305.52159Price 161.40396 | +89.3% | |
| 157.460 | 297.58169Price 157.46471 | +89.0% | |
| 217.560 | 405.38304Price 217.56507 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.